Overseas AI4S Top 30 highlights layered validation standards
Tide AI selected 30 representative overseas AI for Science companies across materials and chemistry, AI drug discovery, and other scientific intelligence, with 10 in each group. The survey distinguishes benchmark leadership, clinical-stage assets, software revenue and renewals, and conditional partnership value as separate evidence. It also notes that the order is neither an investment rating nor a market ranking, and that company-reported benchmarks, partnership terms, and milestones do not by themselves establish realized revenue, clinical success, or reproducibility.
The survey presents a limited-sample view of differentiated validation standards: software companies must show revenue, contract value and renewals; platform companies must show customer reuse and experimental results; and pipeline companies must ultimately produce clinical readouts. It therefore frames AI4S funding as increasingly requiring verifiable outputs, reproducible experiments and sustainable commercial cash flow rather than model claims alone.
AI for Science的融资新闻,很容易被写成另一张金额榜。
潮涌AI在《巨头哄抢AI制药,落点在AI4S》一文里阐述过科技企业和药企为什么同时愿意往科学发现里砸钱。
但模型在基准测试上领先、候选药进入Ⅲ期临床、软件产生两亿美元收入,是三件不同的事;药企给出最高可达十亿美元的合作,也不等于这笔钱已经到账......
为此,潮涌AI筛选出海外AI4S赛道里的30家代表性企业(综合技术验证、商业化证据、融资与产业合作,分材料与化学、AI制药、其余科学智能三个方向,各选10家),结合海外企业的发展现状与前沿布局,共同探寻持续升温的 AI4S 浪潮,将奔赴何方。
以下为潮涌编辑部整理,先后次序不代表投资评级和市场排名——
01
材料与化学:先进入研发流程,再接受实验检验
01 Schrödinger:收入最清楚,也最能看见投入成本
Some source content is omitted. Continue reading on the original site.
#Schrödinger#SandboxAQ#Quantinuum#CuspAI#Periodic Labs#Citrine Informatics#Uncountable#Radical AI#Aether Biomachines#Chai Discovery#Generate Biomedicines#Recursion